Sandbox:Mitra: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Undo revision 1647093 by Mitra Chitsazan (talk) Tag: Undo |
||
Line 7: | Line 7: | ||
{{familytree | | | |!| | | | |!| | | | |!| | | |!| | | |!| | | | |!| | | |}} | {{familytree | | | |!| | | | |!| | | | |!| | | |!| | | |!| | | | |!| | | |}} | ||
{{familytree | | | C01 | | | C02 | | | C03 | | C04 | | C05 | | | C06 |C01=<div style="float: Center; text-align: Center; width: 5em; padding:2em;"> •'''Thrmobolytics''' <br> •'''Percutaneous coronary intervention (PCI)''' <br> | {{familytree | | | C01 | | | C02 | | | C03 | | C04 | | C05 | | | C06 |C01=<div style="float: Center; text-align: Center; width: 5em; padding:2em;"> •'''Thrmobolytics''' <br> •'''Percutaneous coronary intervention (PCI)''' <br> | ||
|C02= <div style="float: Center; text-align: | |C02= <div style="float: Center; text-align: left;"> • '''Avoidance of preload reducing agents''', such as:<br> | ||
:❑Nitrates | :❑Nitrates | ||
:❑Diuretics | :❑Diuretics | ||
Line 13: | Line 13: | ||
• '''In patients with hypotension (without pulmonary congestion): | • '''In patients with hypotension (without pulmonary congestion): | ||
:❑ Intravenous administration of Fluids (N/S 0.9% at 40mL for 2L, to maintain CVP <15mmHg and PCWP between 18-24 mmHg) | :❑ Intravenous administration of Fluids (N/S 0.9% at 40mL for 2L, to maintain CVP <15mmHg and PCWP between 18-24 mmHg) | ||
|C03=<div style="float: Center; text-align: | |C03=<div style="float: Center; text-align: left;"> • '''Systemic or pulmonary vasodilators:'''<br> | ||
: | :❑Nitrosrusside | ||
: | :❑Inhaled nitric oxide | ||
|C04=<div style="float: Center; text-align: | |C04=<div style="float: Center; text-align: left;"> • '''In patients with bradyarrhthmias:'''<br> | ||
: | :❑Atropine | ||
: | :❑Pacemaker | ||
• '''In patients with atrioventricular block:'''<br> | • '''In patients with atrioventricular block:'''<br> | ||
: | :❑Temporary dual-chamber pacemaker | ||
|C05=<div style="float: Center; text-align: | |C05=<div style="float: Center; text-align: left;"> '''In patients with refractory hypotension:'''<br> | ||
: | :❑Dobutamine (along with fluids) | ||
: | :❑Other inotropes: | ||
*milrinone | *milrinone | ||
*norepinephrine | *norepinephrine | ||
|C06= <div style="float: Center; text-align: | |C06= <div style="float: Center; text-align: left;"> • '''May be needed in patients with cardiogenic shock secondary to RVMI''': | ||
: | :❑Direct RV support | ||
: | :❑Indirect RV support | ||
: | :❑Biventricular support}} | ||
<br><br> | <br><br> | ||
{{familytree/end}} | {{familytree/end}} |
Revision as of 15:40, 4 August 2020
Therapuetic Considerations in RVMI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reperfusion | Maintenance of RV preload | Decrease RV afterload | Restoring Rate/Rhythm and AV synchrony | Inotropic support | Mechanical Circulatory Support | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Thrmobolytics •Percutaneous coronary intervention (PCI) | • Avoidance of preload reducing agents, such as:
• In patients with hypotension (without pulmonary congestion):
| • Systemic or pulmonary vasodilators: | • In patients with bradyarrhthmias: • In patients with atrioventricular block:
| In patients with refractory hypotension:
| • May be needed in patients with cardiogenic shock secondary to RVMI:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Do's
- Right ventricular myocardial infarction (RVMI) should be ruled out in all patients presenting with acute inferior wall myocardial infarction, in particular in patients with hypotension.
- In patients presenting with chest pain and clinical findings of hypotension, elevated JVP and clear lung fields, consider the differential diagnoses of RVMI. These include:
- Systemic or pulmonary vasodilators may be considered in selected patients to reduce RV afterload, thereby improving cardiac output.
- In patients with severe tricuspid regurgitation due to RVMI, replacement of tricuspid valve or repair of the valve with annuloplasty rings may be considered.
- In patients with RVMI who have unexplained hypoxemia despite administration of 100% oxygen, right-to-left shunting -through a patent foramen ovale or atrial septal defect-, caused by the disproportionate elevation in right-sided filling pressures compared to the normal or slightly increased left-sided filling pressures should be considered.
- Patients with extensive necrosis due to RVMI may be at higher risk of right ventricular perforation during interventional procedures. Right ventricular catheterization or pacemaker insertion should be performed with great care in these patients.
Don'ts
- In patients with RVMI, avoid preload-reducing agents such as nitrates, diuretics, morphine, beta-blockers, and calcium channel blockers.